Navigation Links
Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
Date:11/17/2009

CAMBRIDGE, Mass., Nov. 17 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company, announced today additional preliminary results from an ongoing Phase 1 study of its lead development candidate, XMT-1001, in patients with advanced solid tumors. The results were presented in a poster session at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in Boston, MA November 15-19, 2009. XMT-1001 is a conjugate of the broad-spectrum cytotoxic camptothecin (CPT) that employs Mersana's Fleximer® platform.

XMT-1001 has continued to demonstrate promising tumor activity and favorable pharmacokinetic and tolerability profiles in the Phase 1 trial. Forty nine patients with refractory solid tumors have received 149 cycles of XMT-1001 at dose levels ranging from 1.0-85 mg CPT equivalents/m2. Twelve of 46 evaluable patients with advanced, refractory tumors demonstrated evidence of at least six weeks of stable disease. Nine of the 12 patients had prolonged stable disease for at least 12 weeks, including two patients for nine months. In addition, pharmacokinetic data for XMT-1001 have demonstrated dose proportional increases in exposure to the drug and confirms the formation of its release products according to the compound's design. The side-effect profile of XMT-1001 has been predictable and no toxicities associated with non-Fleximer-linked CPT or irinotecan, such as hemorrhagic cystitis or severe diarrhea, have been observed. The maximum tolerated dose (MTD) has not been reached and the Phase 1 study continues to accrue patients.

"We are very pleased to see that the data in this ongoing Phase 1 study for XMT-1001 continues to support our goal of establishing proof of concept for the Fleximer platform," said Julie Olson, Chief Executive Officer of Mersana. "Since our last report at ASCO, we have reached higher dose levels, but the MTD for XMT-1001 has not yet been reached. We have enrolled substantially more subjects and continue to see prolonged stable disease and a favorable pharmacokinetic profile. We look forward to concluding the study once the MTD has been reached and continuing to optimize the dosing and treatment regimen for XMT-1001 in a Phase 2 trial next year."

Poster Information

"A Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an intravenous infusion once every three weeks to patients with advanced solid tumors," was authored by, E. Sausville, L. Garbo, G. J. Weiss, D. Shkolny, A. V. Yurkovetskiy, C. Bethune, R. Ramanathan, R. J. Fram; University of Maryland, Baltimore, MD; New York Oncology Hematology, Albany, NY; Scottsdale Clinical Research Institute/TGen, Scottsdale, AZ; Mersana Therapeutics, Inc., Cambridge, MA; Covance Bioanalytical, Madison, WI.

The poster was presented on Tuesday, November 17, 2009, from 12:30 PM to 2:30 PM and from 5:30 PM to 7:30 PM.

About the XMT-1001 Preliminary Study

The Phase 1 trial is an open label, dose escalation study of XMT-1001 administered as an IV infusion once every three weeks in patients with advanced solid tumors. The objectives of the study are to determine the maximum tolerated dose (MTD) as well as to assess safety and pharmacokinetics.

About Fleximer®

Fleximer is a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules, biologics and nucleic acids to enhance their pharmacokinetics and safety, potentially transforming existing and experimental agents into new, patentable drugs with superior properties. The Fleximer platform has broad and versatile applications across therapeutic categories and for enhancing the delivery of all types of therapeutics. Mersana's internal pipeline was generated with the Fleximer platform.

About Mersana Therapeutics, Inc.

Mersana Therapeutics employs its biodegradable polymer platform (Fleximer®) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas. For more information, visit www.mersana.com.

Fleximer® is a trademark of Mersana Therapeutics, Inc.

SOURCE Mersana Therapeutics, Inc.


'/>"/>
SOURCE Mersana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):